Novo Nordisk ( NVO 0.15%) has found phenomenal success in treating patients with obesity and diabetes. *Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan. 3, ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Ahead of the 2025 J.P. Morgan Healthcare Conference scheduled to take place in a few days, Oppenheimer named five potential buyout candidates in biotech on Friday, naming obesity drug developer Viking ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $4,177.57 today based on a ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Nordic firms have outperformed those from the rest of Europe over the past decade. In all four countries, listed ...